We help you join the dots...

RAS LSS is a niche strategy consultancy serving the global life sciences sector

 
 

Starting with Information Services in 2014, RAS LSS has evolved into a boutique healthcare consulting group. We offer a niche portfolio of Strategy Support and Information Services to Pharmaceutical and Medical Device Companies, throughout the product life-cycle.

We elucidate and contextualize current and future market complexities. Leveraging our collective intelligence, we strive to help our clients succeed via

  • Best In Class Situation Analysis
  • Competitively Differentiated Strategy
With an outreach across mature and emerging markets, we go the extra mile to create fresh perspectives for our clients in their mission to reduce the global burden of disease.


We have put in the hours and the sweat to be credible…


Latest Blogs

June 14, 2019
AI/ ML

Recommended AI-ML Abstracts from ASCO 2019

Beyond the hype surrounding #ArtificalIntelligence, #MachineLearning and #DeepLearning, there are several serious research groups working on developing AI based technologies to improve healthcare. At ASCO19, several academic and industry groups presented the outcomes of their research in developing tools for improving oncology healthcare. The range of presentations was wide – […]
June 4, 2019
Hepatobiliary-cancer

Recommended Hepatobiliary Cancer Abstracts from ASCO 2019

Related Post Recommended AI-ML Abstracts from ASCO 2019 Recommended Breast Cancer Abstracts from ASCO 2019 Recommended Esophageal/Gastric Cancer Abstracts from ASCO 2019
June 3, 2019
breast-cancer-tumor

Recommended Breast Cancer Abstracts from ASCO 2019

Related Post Recommended AI-ML Abstracts from ASCO 2019 Recommended Hepatobiliary Cancer Abstracts from ASCO 2019 Recommended Esophageal/Gastric Cancer Abstracts from ASCO 2019
June 1, 2019
gastric-cancer

Recommended Esophageal/Gastric Cancer Abstracts from ASCO 2019

Related Post Recommended AI-ML Abstracts from ASCO 2019 Recommended Hepatobiliary Cancer Abstracts from ASCO 2019 Recommended Breast Cancer Abstracts from ASCO 2019
June 1, 2019
Io_resistance

What to expect on I-O Resistance at ASCO 2019?

Related Post Recommended AI-ML Abstracts from ASCO 2019 Recommended Hepatobiliary Cancer Abstracts from ASCO 2019 Recommended Breast Cancer Abstracts from ASCO 2019
August 16, 2018
egfr_lung_cancer

1L EGFRm+ NSCLC competition – Where are we heading to?

1L EGFRm+ Lung cancer is rapidly evolving and changing. Tagrisso is leading the pack with ORR of 77% and PFS of 18.9 mos. However, talking about overall survival, Dacomitinib is currently leading with OS of 34.1 mos. As Tagrioss’s final OS data is yet to be declared, the OS in […]